Wendi Hu

1.4k total citations · 1 hit paper
23 papers, 1.0k citations indexed

About

Wendi Hu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Wendi Hu has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Wendi Hu's work include RNA modifications and cancer (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Wendi Hu is often cited by papers focused on RNA modifications and cancer (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Wendi Hu collaborates with scholars based in China, Madagascar and United States. Wendi Hu's co-authors include Shusen Zheng, Haiyang Xie, Jian Wu, Chuanhui Peng, Junru Chen, Yunhao Chen, Lin Zhou, Beng Yang, Bin He and Yanpeng Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Wendi Hu

22 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1

2019 479 citations Yunhao Chen, Chuanhui Peng et al. Molecular Cancer profile →

Peers

Countries citing papers authored by Wendi Hu

Since Specialization

Citations

This map shows the geographic impact of Wendi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendi Hu more than expected).

Fields of papers citing papers by Wendi Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendi Hu. The network helps show where Wendi Hu may publish in the future.

Co-authorship network of co-authors of Wendi Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Wendi Hu. A scholar is included among the top collaborators of Wendi Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendi Hu. Wendi Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Robotic pancreatoduodenectomy reduces grade B pancreatic fistula in patients with a small main pancreatic duct: a propensity score-matched study compared to laparoscopic pancreatoduodenectomy 2025 ·Annals of Medicine ·(unknown), Xiaoyu Zhang, Wei Chen, (unknown), Xiang Li, Yiwen Chen, Wendi Hu, (unknown), Jiaqi Yang, Xueli Bai, Tingbo Liang	0
2	Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study 2024 ·Signal Transduction and Targeted Therapy ·Yiwen Chen, (unknown), Wendi Hu, Xiang Li, Ke Sun, Yan Shen, (unknown), Jian Wu, Shunliang Gao, Jun Yu, Risheng Que, Yun Zhang, Fuchun Yang, Weiliang Xia, Aibin Zhang, Xiaofeng Tang, Xueli Bai, (unknown)	6
3	Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study. 2024 ·Journal of Clinical Oncology ·Xueli Bai, (unknown), (unknown), Wendi Hu, Xiang Li, Yan Shen, (unknown), Jian Wu, Shunliang Gao, (unknown), Risheng Que, Yun Zhang, Fuchun Yang, Weiliang Xia, Aibin Zhang, Xiaofeng Tang, Tingbo Liang	1
4	Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study. 2023 ·Journal of Clinical Oncology ·Tingbo Liang, Yiwen Chen, (unknown), Wendi Hu, Xiang Li, Junhui Sun, (unknown), Min Zhang, Jian Wu, Shunliang Gao, (unknown), Risheng Que, Yun Zhang, Fuchun Yang, (unknown), Aibin Zhang, Xiaofeng Tang, Xueli Bai	3
5	Palladium supported on pyrrole functionalized hypercrosslinked polymer: Synthesis and its catalytic evaluations towards Suzuki-Miyaura coupling reactions in aqueous media 2022 ·Journal of Molecular Liquids ·Yahao Dong, (unknown), Yanan Wang, Xinjuan Li, Tao Li, (unknown), Wendi Hu, Linbo Zhang, Xinhui Zhang, Chunyan Weı	18
6	C8orf76 Modulates Ferroptosis in Liver Cancer via Transcriptionally Up-Regulating SLC7A11 2022 ·Cancers ·Duguang Li, Junhai Pan, Yiyin Zhang, Yirun Li, (unknown), Cheng Zhong, Peng Chen, Jingjing Ma, Wendi Hu, Xiaoxiao Fan, Hui Lin	18
7	Hyperoside suppresses BMP-7-dependent PI3K/AKT pathway in human hepatocellular carcinoma cells 2021 ·Annals of Translational Medicine ·Shuang Wei, Yun Sun, Li Wang, Tianfang Zhang, Wendi Hu, Wangxiao Bao, (unknown), Jinxiu Chen, Haijun Li, Yankai Wen, Zuobing Chen	19
8	ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway 2020 ·Cancer Letters ·Junru Chen, Chaofeng Ding, Yunhao Chen, Wendi Hu, (unknown), Chuanhui Peng, Xiaode Feng, Qiyang Cheng, Wenxuan Wu, Yuejie Lu, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng	162
9	ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis 2020 ·Oncogenesis ·Junru Chen, Chaofeng Ding, Yunhao Chen, Wendi Hu, Yuejie Lu, Wenxuan Wu, Yanpeng Zhang, Beng Yang, Hao Wu, Chuanhui Peng, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng	71
10	WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1 breakdown → 2019 ·Molecular Cancer ·Yunhao Chen, Chuanhui Peng, Junru Chen, Diyu Chen, Beng Yang, Bin He, Wendi Hu, Yanpeng Zhang, Hua Liu, Longfei Dai, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng	479
11	PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma 2019 ·Clinics and Research in Hepatology and Gastroenterology ·(unknown), Wendi Hu, Zhen Lv, Hua Liu, Diyu Chen, (unknown), Jian Wu, Shusen Zheng	25
12	Targeting Mybbp1a suppresses HCC progression via inhibiting IGF1/AKT pathway by CpG islands hypo-methylation dependent promotion of IGFBP5 2019 ·EBioMedicine ·Xiaoyu Weng, Jingbang Wu, Zhen Lv, Chuanhui Peng, Junru Chen, Cheng Zhang, Bin He, Rongliang Tong, Wendi Hu, Chaofeng Ding, Linping Cao, Diyu Chen, Jian Wu, Shusen Zheng	24
13	Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis 2019 ·Laboratory Investigation ·Longfei Dai, Wendi Hu, (unknown), Diyu Chen, Bin He, Yunhao Chen, Lin Zhou, Haiyang Xie, Jian Wu, Shusen Zheng	16
14	LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells. 2019 ·PubMed ·Ronggao Chen, Yiting Qiao, Wendi Hu, Qiyang Cheng, Haiyang Xie, Lin Zhou, Xiao Xu, Shusen Zheng, Donghai Jiang	3
15	Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma 2018 ·Laboratory Investigation ·Weijian Sun, Bin He, Beng Yang, Wendi Hu, Shaobing Cheng, Heng Xiao, (unknown), Xiaoyu Wen, Lin Zhou, Haiyang Xie, Xian Shen, Jian Wu, Shusen Zheng	42
16	Over Expression of Long Non-Coding RNA PANDA Promotes Hepatocellular Carcinoma by Inhibiting Senescence Associated Inflammatory Factor IL8 2017 ·Scientific Reports ·Chuanhui Peng, Wendi Hu, Xiaoyu Weng, Rongliang Tong, Shaobing Cheng, Chaofeng Ding, Heng Xiao, Zhen Lv, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng	28
17	Autophagy blockade enhances the anti-cancer effect of Romidepsin in gastric cancer 2017 ·Translational Cancer Research ·Weijian Sun, Bin He, Beng Yang, Wendi Hu, Jian Wu, Shusen Zheng	1
18	Mixed serous neuroendocrine neoplasm of the pancreas 2016 ·Medicine ·Yatong Li, Menghua Dai, Xiaoyan Chang, Wendi Hu, Jie Chen, Junchao Guo, Wenming Wu, Taiping Zhang, (unknown), Ziwen Liu, Ya Hu, (unknown)	6
19	Expression and Critical Role of Interleukin Enhancer Binding Factor 2 in Hepatocellular Carcinoma 2016 ·International Journal of Molecular Sciences ·Shaobing Cheng, Xu Jiang, Chaofeng Ding, Chengli Du, Kwabena Gyabaah Owusu-Ansah, Xiaoyu Weng, Wendi Hu, Chuanhui Peng, Zhen Lv, Rongliang Tong, Heng Xiao, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng	28
20	Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma 2015 ·Journal of Experimental & Clinical Cancer Research ·Chengli Du, Xiaoyu Weng, Wendi Hu, Zhen Lv, Heng Xiao, Chaofeng Ding, (unknown), Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact